ReviewExpert opinion on therapeutic targets2012
The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.
Review in Expert opinion on therapeutic targets, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 49 citations in OpenAlex.
- Efficacy profile of a bivalent Staphylococcus aureus glycoconjugated vaccine in adults on hemodialysis: Phase III randomized study.Human vaccines & immunotherapeutics · 2015Trial
- Phenotypic and Genotypic Characterization ofPathogens (Basel, Switzerland) · 2025Article
- Critical Assessment of the Prospects of Quorum-Quenching Therapy forInternational journal of molecular sciences · 2023Review
- Accessory Gene Regulator (Frontiers in microbiology · 2022Article
- Engineered Biomimetic Platelet Membrane-Coated Nanoparticles BlockEngineering (Beijing, China) · 2021Article
- Article
- Multifunctional Amyloids in the Biology of Gram-Positive Bacteria.Microorganisms · 2020Review
- Article
- Protective Efficacy of Monoclonal Antibodies Neutralizing Alpha-Hemolysin and Bicomponent Leukocidins in a Rabbit Model of Staphylococcus aureus Necrotizing Pneumonia.Antimicrobial agents and chemotherapy · 2020Article
- Antimicrobial approaches in the prevention of Staphylococcus aureus infections: a review.The Journal of antimicrobial chemotherapy · 2019Review
- Evolving concepts in bone infection: redefining "biofilm", "acute vs. chronic osteomyelitis", "the immune proteome" and "local antibiotic therapy".Bone research · 2019Review
- Identification, cloning and characterization of SpEX exotoxin produced by Staphylococcus pseudintermedius.PloS one · 2019Article
- Recent advances inInfection and drug resistance · 2019Review
- Article
- Therapeutic Targeting of theFrontiers in microbiology · 2018Review
- Article
- Commercial Intravenous Immunoglobulin Preparations Contain Functional Neutralizing Antibodies against the Staphylococcus aureus Leukocidin LukAB (LukGH).Antimicrobial agents and chemotherapy · 2017Article
- VLP-based vaccine induces immune control of Staphylococcus aureus virulence regulation.Scientific reports · 2017Article
- Antimicrobial and Antibiofilm Potential of Acyclic Amines and Diamines against Multi-Drug ResistantFrontiers in microbiology · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
introductionThe pandemic human pathogen, Staphylococcus aureus, displays high levels of antibiotic resistance and is a major cause of hospital- and community-associated infections. S. aureus disease manifestation is to a great extent due to the production of a large arsenal of virulence factors, which include a series of secreted toxins. Antibodies to S. aureus toxins are found in people who are infected or asymptomatically colonized with S. aureus. Immunotherapies consisting of neutralizing anti-toxin antibodies could provide immediate aid to patients with impaired immune systems or in advanced stages of disease. AREAS COVERED: Important S. aureus toxins, their roles in pathogenesis, rationales for selecting S. aureus toxins for immunization efforts, and caveats associated with monoclonal antibody-based passive immunization are discussed. This review will focus on hyper-virulent community-associated methicillin-resistant S. aureus because of their recent surge and clinical importance. EXPERT OPINION: Antibodies against genome-encoded toxins may be more broadly applicable than those directed against toxins found only in a sub-population of S. aureus isolates. Furthermore, there is substantial functional redundancy among S. aureus toxins. Thus, an optimal anti-S. aureus formulation may consist of multiple antibodies directed against a series of key S. aureus genome-encoded toxins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.